Usually each 300 Unit vial of Dyston® is to be reconstituted with 1.5 mL and each 500 Unit vial of Dyston® is to be reconstituted with 2.5 mL of preservative-free %0.9 Sodium Chloride Injection prior to administration. The concentration of the resulting solution will be 20 Units per 0.1 mL.

- **When using 2.5 mL of diluent for a 500 Unit vial of Dyston®, complete the following steps:**



Using an appropriately sized sterile syringe (e.g., a 3 mL syringe), needle and aseptic technique, draw up 2.5 mL of preservative-free %0.9 Sodium Chloride Injection.

Insert the needle into the 500 Unit vial. The partial vacuum will begin to draw the saline into the vial. Any remaining required saline should be expressed into the vial manually. gently swirl the vial to dissolve.





Draw the required patient dose of Dyston® into a sterile syringe and dilute with additional preservative-free %0.9 Sodium Chloride Injection, if required, to achieve the final volume for injection.

Expel any air bubbles in the syringe barrel. Remove the needle used to reconstitute the product and attach a new appropriately sized new sterile needle. Use the content of the syringe immediately. Dispose of any unused saline solution.

Dosage and Indications Based on Literature Review

Expert opinion and clinical experience emphasize the importance of tailoring treatment to each patient's unique facial anatomy, muscle mass distribution, and specific treatment goals, rather than relying solely on standardized templates for the dosages and injection sites of BONT-A.

Indication	Dosage (U) [1-12]
Glabellar lines (procerus and corrugator muscles)	50 Units (Inject 10 Units into each of 5 sites; 2 injections in each corrugator muscle and 1 injection in the procerus muscle)
Forehead lines (frontalis muscle)	30-60 units
Crow's feet (orbicularis oculi muscles)	30 to 90 units(5-15 units injectedat 3 sites around each eye)
Brow lift (orbicularis oculi)	10-12 units total
Lower eyelid rhytids (orbicularis oculi muscle)	3-7 units per side
Bunny lines (nasalis muscle)	5-10 units per side; additional 3-5 units centrally if necessary
Drooping nasal tip	10 units
Smoker's lines (orbicularis oris muscle)	4-12 units
Gummy smile	3-7 units per side
Marionette line (depressor anguli oris)	20 units per side
Masseter hypertrophy	30-60 units per side
Dimpled chin (mentalis muscle)	10-20 units
Platysmal band	40-80 units per band
Decollete wrinkles	75-120 units
Primary hyperhidrosis	100 to 200 Unit per axilla (10 to 20 injections)





References

1. Matarasso A, Shafer D. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide. Aesthet Surg J. 2009;29(6 Suppl):S72-S79.
2. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest. J Eur Acad Dermatol Venereol. 2010;24(11):1285-1295.
3.Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles. J Eur Acad Dermatol Venereol. 2010;24(11):1278-1284.
4. Dysport (abobotulinumtoxinA) [package insert]. Scottsdale, AZ: Medicis Aesthetics; 2009.
5. Rzany B, Dill-Müller D, Grablowitz D, Heckmann M, Caird D; German-Austrian Retrospective Study Group. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg. 2007;33(1 Spec No.):S18-S25.
6. Kane MAC, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg. 2009;124(5):1619-1629.
7. Farahvash MR, Arad S. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience. J Cosmet Dermatol. 2007;6(3):152-158.
8. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149(5):1041-1045.
9. Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004;114(6 Suppl):1S-22S.
10. Lowe NJ, Yamauchi P. Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clin Dermatol. 2004;22(1):18-22.
11. Talarico-Filho S, Mendonça DO Nascimento M, Sperandeo DE Macedo F, DE Sanctis Pecora C. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No.):S44-S50.
12. Arikan OK, Tan FU, Kendi T, Koc C. Use of botulinum toxin type A for the treatment of masseteric muscle hypertrophy. J Otolaryngol. 2006;35(1):40-43.